MedTrace Logo

Tinnitus Treatment With Piribedil Guided by Acoustic Otoemissions and Electrocochleography

NCT00591994 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2008-03-07

No results posted yet for this study

Summary

Tinnitus is defined as the perception of sound in the absence of a external source. About 15 % of the population is believed to experience tinnitus and for about 20 % of them it may become a very serious problem. Total comprehension of tinnitus pathophysiology has not yet been achieved, but modern theories focus in brain hyperactivity following inner ear damage, with involvement of various neurotransmitters. Piribedil,a dopamin agonist, has been used to treat tinnitus, focusing in dopamine release, which is inhibitory. Electrophysiological methods,like acoustic otoemissions and electrocochleography may reveal the changes in peripherical and central auditory pathways and help to choose the specific patients who could benefit from piribedil treatment.

Conditions

  • Tinnitus

Interventions

DRUG

piribedil

50 mg once a day, after lunch 3 month therapy

Sponsors & Collaborators

  • Faculdade de Medicina de Valenca

    lead OTHER

Principal Investigators

  • Ricardo R Figueiredo, M.D.,M.Sc · Faculdade de Medicina de Valença

  • Andréia A Azevedo, M.D. · Otosul -Otorrinolaringologia Sul-Fluminense

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2007-12-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00591994 on ClinicalTrials.gov